Pyrrolo[2,1-c][1,4]benzodiazepine as a scaffold for the design and synthesis of anti-tumour drugs.
Compounds that bind in the minor groove of DNA have found use in the experimental treatment of cancer and certain infectious diseases. Furthermore, agents which target and can recognize discrete sequences of DNA have the potential to offer selective therapies by modulating the activity of specific transcription factors or genes. For this reason, a number of sequence-selective DNA binding agents have been evaluated with a range of affinities and recognition fidelities. In this respect, the pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are of interest as they bind to guanine residues in the minor groove with a preference for Pu-G-Pu sequences. A dramatic increase in cytotoxicity and sequence selectivity has been achieved by linking two PBD units to form PBD dimers as cross-linking agents on opposite DNA strands (e.g., interstrand cross-links). SJG-136 is currently undergoing Phase I evaluation in both the United States (through the NCI) and United Kingdom (through Cancer Research United Kingdom). This review will focus on design, synthesis and structure activity relationship studies of pyrrolobenzodiazepines as anticancer therapeutics reported since 2003.
Cipolla
Laura
L
Dept. of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126, Milano, Italy. laura.cipolla@unimib.it
Araújo
Ana C
AC
Airoldi
Cristina
C
Bini
Davide
D
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D001569:Benzodiazepines / Q000737:chemistry* / Q000627:therapeutic use*; D001665:Binding Sites; D004247:DNA / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D011758:Pyrroles / Q000737:chemistry* / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D011758:Pyrroles; C438462:pyrrolo(2,1-c)(1,4)benzodiazepine; D001569:Benzodiazepines; D004247:DNA